Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.48 |
| ▸ | CNR2 | P34972 | 6/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.36 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3863581 | 0.86 | BRD4 (0.50) | BRD4CNR2CNR1PIK3CAPIK3CD | |
| SCHEMBL4791340 | 0.85 | BRD4 (0.47) | BRD4CNR2CNR1PIK3CAPIK3CD | |
| SCHEMBL2115527 | 0.83 | BRD4 (0.45) | BRD4CNR2CNR1PIK3CAPIK3CD | |
| SCHEMBL5471088 | 0.83 | BRD4 (0.45) | BRD4CNR2CNR1PIK3CAPIK3CD | |
| SCHEMBL4790618 | 0.83 | BRD4 (0.50) | BRD4CNR2CNR1PIK3CAPIK3CD | |
| SCHEMBL5454598 | 0.81 | BRD4 (0.41) | BRD4CNR2CNR1PIK3CAPIK3CD | |
| SCHEMBL4763449 | 0.79 | BRD4 (0.50) | BRD4CNR2CNR1PIK3CAPIK3CD | |
| SCHEMBL14466814 | 0.79 | PIK3CA (0.43) | BRD4CNR2CNR1PIK3CAPIK3CD | |
| SCHEMBL3867837 | 0.77 | TLR7 (0.39) | BRD4CNR2CNR1TLR7 | |
| SCHEMBL4543189 | 0.77 | BRD4 (0.49) | BRD4CNR2CNR1PIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8158794-B2 | Hydroxyalkyl substituted imidazoquinoline compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | BRD4 1092/4885CNR2 2464/4885CNR1 2720/4885 |
| US-20090069314-A1 | Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods | IFNG, IRF3, IFNAR1 | BRD4 274/4885CNR2 1771/4885CNR1 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.